Cephalon Plunks Down $225M Now, $300M Later for Gemin X
By Staff Reports
Tuesday, March 22, 2011
Gemin X Pharmaceuticals Inc., a firm that had been on the prowl for a partner after wowing Wall Street a couple of years ago with early stage data for small-cell lung cancer (SCLC) candidate obatoclax, was snatched up by Cephalon Inc. for $225 million up front.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.